Canada Grants Monopoly To Historically Terrible MMJ Producer

Prairie Plant Systems once held a monopoly over commercial MMJ in Canada. The product they produced received an enormous number of complaints, even after being delayed by Health Canada to ensure safety and quality. About 30% of patients actually returned the product the first 6 months of distribution.

The company claimed that its product contained only 10% THC, which would have been discouraging enough if it wasn’t a gross overestimate; testing later showed the product to be about 5% THC, and contained ground stems and stalks. The PPS growing facility was located over 1,000 feet underground in a contaminated mine, and was shown to contain alarming levels of lead and arsenic.

None of this seems to matter to Health Canada, who just granted both of the first licenses under the MMPR to Prairie Plant Systems and one of its subsidiaries. None of this seems to matter to the company either, whose CEO Brent Zettl stated in a press release:

Patient safety is our primary focus, which means that patients and their healthcare professionals can trust our consistent and reliable product every time. We have a quality control process with 281 points of control, ensuring that there is no variability, giving patient’s confidence in dose consistency.